-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Reiterates Buy on BridgeBio Pharma, Maintains $100 Price Target

Benzinga·04/29/2026 12:02:49
Listen to the news
HC Wainwright & Co. analyst Raghuram Selvaraju reiterates BridgeBio Pharma (NASDAQ:BBIO) with a Buy and maintains $100 price target.